Table 2.

“ex vivo, in vitro” persistent “presynaptic adaptation” in synaptosomes.

In Vivo Treatment		“Ex Vivo, In Vitro” Synaptosomes Adaptations
Drug	Treatment	Synaptosomal Preparation	Transmitter	Stimulus Applied	Outcome	Ref.
reboxetine	10 mg/Kg, os	rat hippocampus	[3H]noradrenaline	12 mM KCl	⇓	[8]
reboxetine	10 mg/Kg, os	rat hippocampus	[3H]serotonin	12 mM KCl	⇓	[8]
desipramine	10 mg/Kg, i.p.	mice cortex	[3H]noradrenaline	12 mM KCl	⇓	[71]
Desipramine-yohimbine	10 mg/Kg i.p. 0.5 mg/Kg i.p.	mice cortex	[3H]noradrenaline	12 mM KCl	No effect	[71]
fluoxetine	10 mg/Kg, i.p.	Rat hippocampus	[3H]serotonin	12 mM KCl	⇓	[8]
fluoxetine	10 mg/Kg, i.p.	Rat hippocampus	[3H]noradrenaline	12 mM KCl	No effect	[8]
LY379268	1 mg/Kg, i.p.	Mouse spinal cord	[3H]D-aspartate	15 mM KCl	⇓	[76]

The table summarizes the results from “ex vivo, in vitro” experiments showing a persistent adaptation in synaptosomes elicited by “in vivo” acute administration of drugs that modulate the functions of presynaptic release-regulating receptors. It is proposed that the acute administration of receptor ligands or carrier modulators elicit functional remodeling of the synaptic proteasome. The persistent “in vivo” adaptive changes in synaptic boutons are retained by nerve endings, after isolation from the hippocampus and washing with drug-free solutions, and emerge in “ex vivo, in vitro” study as reduced exocytosis efficiency. ⇓= reduced.